The Global Health Body Issues Alert Over Acute Shortage of Obesity Medications
Fewer than one in 10 individuals eligible to benefit from GLP-1 drugs including Wegovy are able to get them, warns the WHO as it releases its first guidance on the medications.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging broader and more equitable access to this class of drugs.
Based on estimates, more than two billion are projected to be obese by 2030 without intervention.
"The latest guidance affirms that obesity is a long-term condition that can be managed with comprehensive and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are key obstacles to broad availability to the injections that can help people shift significant body mass, says the agency.
Weight-Loss Drug Supply Crisis
Despite the present most optimistic case, the production of GLP-1 therapies could only cover around 100 million people – less than 10% of eligible patients, as stated by the health organization.
The guideline encourages countries and companies to increase availability, by approaches such as voluntary licensing.
Exclusive production rights on semaglutide – the primary ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026.
How Obesity Jabs Function
GLP-1 drugs mimick a biological compound to reduce digestion speed, suppress the appetite and boost the sense of being full so users consume fewer calories.
Patients typically start to lose weight after several weeks of starting on the regular doses.
Evidence points to people may see weight return within a year of halting the treatment, because their usual appetite return.
Being carrying excess weight raises your chance for contracting medical conditions, such as diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight affects people in countries worldwide and was linked to millions of deaths worldwide in 2024, per the health agency.
